Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Allogene Therapeutics, Inc. (ALLO : NSDQ)
 
 • Company Description   
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.?

Number of Employees: 361

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.32 Daily Weekly Monthly
20 Day Moving Average: 1,649,901 shares
Shares Outstanding: 145.84 (millions)
Market Capitalization: $775.88 (millions)
Beta: 0.77
52 Week High: $17.49
52 Week Low: $4.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.52% -20.64%
12 Week -8.12% -14.71%
Year To Date -15.42% -23.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
210 EAST GRAND AVENUE
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-457-2700
fax: -
ir@allogene.com http://www.allogene.com
 
 • General Corporate Information   
Officers
David Chang - President; Chief Executive Officer
Arie Belldegrun - Executive Chairman of the Board of Directors
Eric Schmidt - Chief Financial Officer
Elizabeth Barrett - Director
David Bonderman - Director

Peer Information
Allogene Therapeutics, Inc. (CORR.)
Allogene Therapeutics, Inc. (RSPI)
Allogene Therapeutics, Inc. (CGXP)
Allogene Therapeutics, Inc. (BGEN)
Allogene Therapeutics, Inc. (GTBP)
Allogene Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 019770106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/08/23
Share - Related Items
Shares Outstanding: 145.84
Most Recent Split Date: (:1)
Beta: 0.77
Market Capitalization: $775.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 24.48% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.31
Price/Cash Flow: -
Price / Sales: 3,315.72
EPS Growth
vs. Year Ago Period: -21.43%
vs. Previous Quarter: -3.03%
Sales Growth
vs. Year Ago Period: -14.75%
vs. Previous Quarter: 10.64%
ROE
03/31/23 - -50.21
12/31/22 - -43.44
09/30/22 - -37.74
ROA
03/31/23 - -41.36
12/31/22 - -36.79
09/30/22 - -32.58
Current Ratio
03/31/23 - 8.08
12/31/22 - 9.70
09/30/22 - 11.64
Quick Ratio
03/31/23 - 8.08
12/31/22 - 9.70
09/30/22 - 11.64
Operating Margin
03/31/23 - -150,207.69
12/31/22 - -136,885.59
09/30/22 - -126,580.16
Net Margin
03/31/23 - -150,207.69
12/31/22 - -136,885.59
09/30/22 - -126,580.16
Pre-Tax Margin
03/31/23 - -150,207.67
12/31/22 - -136,885.59
09/30/22 - -126,580.18
Book Value
03/31/23 - 4.06
12/31/22 - 4.62
09/30/22 - 5.15
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©